Patient Rating:

No Rating Available?

John M. Hoffman, M.D.

Patient Rating:

No Rating Available?

Clinical Details

Phone Number Clinical Office Address
(801) 587-4064
Huntsman Cancer Hospital
1950 Circle of Hope
Salt Lake City, UT 84112
Map
(801) 581-2370
University Hospital
Radiology
50 N Medical Dr
Salt Lake City, UT 84132
Map

Bio

John M. Hoffman, MD, is a professor of radiology and neurology and director of nuclear medicine in the Department of Radiology at the University of Utah. He is also director of the Center for Quantitative Cancer Imaging at the Huntsman Cancer Institute. He holds the Willard Snow Hansen Presidential Endowed Chair in Cancer Research.

Board Certification and Academic Information

Academic Departments Radiology and Imaging Sciences - Professor
Neurology - Professor
Academic Divisions Clinical Radiology
Board Certification American Board of Nuclear Medicine (Nuc Med)
Cancer Center Programs Experimental Therapeutics

Academic Profile

Board Certification and Academic Information

Academic Departments Radiology and Imaging Sciences - Professor
Neurology - Professor
Academic Divisions Clinical Radiology
Board Certification American Board of Nuclear Medicine (Nuc Med)
Cancer Center Programs Experimental Therapeutics

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 581-7553 Huntsman Cancer Institute
Radiology
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

John M. Hoffman, MD, is a professor of radiology and neurology and director of nuclear medicine in the Department of Radiology at the University of Utah. He is also director of the Center for Quantitative Cancer Imaging at Huntsman Cancer Institute. He holds the Willard Snow Hansen Presidential Endowed Chair in Cancer Research. Dr. Hoffman's research interests include the use of positron emission tompghraphic imaging (PET) for cancer diagnosis and response to therapy and the study of neurologic diseases.

Education

Education History

Type School Degree
Fellowship UCLA Medical Center
Nuclear Medicine
Fellow
Residency University of Washington
Neurology
Resident
Residency University of Washington
Neurosurgery
Resident
Internship University of Washington
Surgery
Intern
Internship University of Wyoming, College of Human Medicine
Internship
Intern
Professional Medical University of Colorado School of Medicine
M.D.
Undergraduate University of Pennsylvania
Bioengineering
B.S.E.

Publications

Selected Provider Publications

Journal Article

  1. Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, Perlman ES, Kinahan PE, Christian PE, Hoekstra OS, Dorfman GS (2015). Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials. J Nucl Med, 56(6), 955-61.
  2. Duff K, Horn KP, Foster NL, Hoffman JM (2015). Short-Term Practice Effects and Brain Hypometabolism: Preliminary Data from an FDG PET Study. Arch Clin Neuropsychol, 30(3), 264-70.
  3. Edwards O, Yakish ED, Wang LM, Wu Q, Hoffman JM, Morton KA (2015). Histamine Receptor 1 and 2 Antagonists Alter Biodistribution of Radioiodine. J Nucl Med Technol, 43(3), 214-9.
  4. Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM (2015). FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging, 15(1), 15.
  5. Duff K, Foster NL, Hoffman JM (2014). Practice effects and amyloid deposition: preliminary data on a method for enriching samples in clinical trials. Alzheimer Dis Assoc Disord, 28(3), 247-52.
  6. Foster NL, Mottola K, Hoffman JM (2014). Coverage With Evidence Development: What to Consider.LID - 10.1001/jamaneurol.2013.5812 [doi]. JAMA Neurol, 71(4), 399-400.
  7. Kadrmas DJ, Rust TC, Hoffman JM (2013). Single-scan dual-tracer FLT+FDG PET tumor characterization. Phys Med Biol, 58(3), 429-49.
  8. Duff K, Foster NL, Dennett K, Hammers DB, Zollinger LV, Christian PE, Butterfield RI, Beardmore BE, Wang AY, Morton KA, Hoffman JM (2013). Amyloid deposition and cognition in older adults: the effects of premorbid intellect. Arch Clin Neuropsychol, 28(7), 665-71.
  9. Marcus RL, Addison O, LaStayo PC, Hungerford R, Wende AR, Hoffman JM, Abel ED, McClain DA (2013). Regional muscle glucose uptake remains elevated one week after cessation of resistance training independent of altered insulin sensitivity response in older adults with type 2 diabetes. J Endocrinol Invest, 36(2), 111-7.
  10. Enslow MS, Zollinger LV, Morton KA, Butterfield RI, Kadrmas DJ, Christian PE, Boucher KM, Heilbrun ME, Jensen RL, Hoffman JM (2012). Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med, 37(9), 854-61.
  11. Rondina MT, Lam UT, Pendleton RC, Kraiss LW, Wanner N, Zimmerman GA, Hoffman JM, Hanrahan C, Boucher K, Christian PE, Butterfield RI, Morton KA (2012). (18)F-FDG PET in the evaluation of acuity of deep vein thrombosis. Clin Nucl Med, 37(12), 1139-45.
  12. Rondina MT, Wanner N, Pendleton RC, Kraiss LW, Vinik R, Zimmerman GA, Heilbrun M, Hoffman JM, Morton KA (2012). A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism. Thromb Res, 129(1), 22-7.
  13. Wang LM, Becker JS, Wu Q, Oliveira MF, Bozza FA, Schwager AL, Hoffman JM, Morton KA (2010). Bioimaging of copper alterations in the aging mouse brain by autoradiography, laser ablation inductively coupled plasma mass spectrometry and immunohistochemistry. Metallomics, 2(5), 348-53.
  14. Wu X, Jeong EK, Emerson L, Hoffman JM, Parker DL, Lu ZR (2010). Noninvasive evaluation of antiangiogenic effect in a mouse tumore model by DCE-MRI with Gd-DTPA cystamine copolymers. Mol Pharm, 7, 41-48.
  15. Spence AM, Muzi M, Link JM, OSullivan F, Eary JF, Hoffman JM, Shankar LK, Krohn KA (2009). NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol, 11(5), 343-55.
  16. Rodrigues RS, Bozza FA, Christian PE, Hoffman JM, Butterfield RI, Christensen CR, Heilbrun M, Wiggins RH 3rd, Hunt JP, Bentz BG, Hitchcock YJ, Morton KA (2009). Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck. J Nucl Med, 50(8), 1205-13.
  17. Pack NA, DiBella EV, Rust TC, Kadrmas DJ, McGann CJ, Butterfield R, Christian PE, Hoffman JM (2008). Estimating myocardial perfusion from dynamic contrast-enhanced CMR with a model-independent deconvolution method. J Cardiovasc Magn Reson, 10(1), 52.
  18. Spence AM, Muzi M, Link JM, Hoffman JM, Eary JF, Krohn KA (2008). NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies. Mol Imaging Biol, 10(5), 271-80.
  19. Neuwelt EA, Varallyay CG, Manninger S, Solymosi D, Haluska M, Hunt MA, Nesbit G, Stevens A, Jerosch-Herold M, Jacobs PM, Hoffman JM (2007). The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery, 60(4), 601-11; discussion 611-2.
  20. Podoloff DA, Advani RH, Allred C, Benson AB 3rd, Brown E, Burstein HJ, Carlson RW, Coleman RE, Czuczman MS, Delbeke D, Edge SB, Ettinger DS, Grannis FW Jr, Hillner BE, Hoffman JM, Kiel K, Komaki R, Larson SM, Mankoff DA, Rosenzweig KE, Skibber JM, Yahalom J, Yu JM, Zelenetz AD (2007). NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw, 5 Suppl 1, S1-22; quiz S23-2.
  21. Hoffman JM, Gambhir SS, Kelloff GJ (2007). Regulatory and reimbursement challenges for molecular imaging. Radiology, 245(3), 645-60.
  22. Neuwelt EA, Vrallyay C, Manninger S, Solymosi D, Hunt MA, Jerosch-Herold M, Stevens A, Nesbit G, Kraemer D, Hoffman JM (2007). Assessment of MR imaging, perfusion, and angiography using ferumoxytol nanoparticles in CNS malignancy. Neurosurgery, 60(4), 601-612.
  23. Rust TC, DiBella EV, McGann CJ, Christian PE, Hoffman JM, Kadrmas DJ (2006). Rapid dual-injection single-scan 13N-ammonia PET for quantification of rest and stress myocardial blood flows. Phys Med Biol, 51(20), 5347-62.
  24. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D (2006). Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol, 82 (10), 699-757.
  25. Shankar LK, Hoffman JM, Bacharach S, Graham M, Karp J, Lammertsma A, Larson S, Mankof D, Siegel B, Van den Abbeele A, Yap J, Sullivan D (2006). Guidelines for the Use of Positron Emission Tomography (PET) and [18F]-2-fluoro-2-deoxy-d-glucose (FDG) as an Indicator of Therapeutic Response in Patients Involved in National Cancer Institute (NCI) Clinical Trials. J Nucl Med, 47(6), 1059-1066 .
  26. Gillies RJ, Hoffman JM, Lam KS, Menkens AE, Piwnica-Worms DR, Sullivan DC, Weissleder R (2005). Meeting report: high-throughput technologies for in vivo imaging agents. Mol Imaging, 4(2), 98-103.
  27. Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, Link JM, Guyton KZ, Eckelman WC, Scher HI, OShaughnessy J, Cheson BD, Sigman CC, Tatum JL, Mills GQ, Sullivan DC, Woodcock J (2005). The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res, 11(22), 7967-85.
  28. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, Oshaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC (2005). Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res, 11(8), 2785-808.
  29. Hoffman JM (2004). Can optical molecular imaging techniques with catheter-based approaches be used for disease detection? Radiology, 231(3), 609-10.
  30. Finkelstein SE, Carrasquillo JA, Hoffman JM, Galen B, Choyke P, White DE, Rosenberg SA, Sherry RM (2004). A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol, 11(8), 731-8.
  31. Schweitzer JB, Lee DO, Hanford RB, Zink CF, Ely TD, Tagamets MA, Hoffman JM, Grafton ST, Kilts CD (2004). Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: normalization of behavior but not related brain activity. Biol Psychiatry, 56(8), 597-606.
  32. Kilts CD, Egan G, Gideon DA, Ely TD, Hoffman JM (2003). Dissociable neural pathways are involved in the recognition of emotion in static and dynamic facial expressions. Neuroimage, 18(1), 156-68.
  33. Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD, Hoffman JM (2003). Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry, 11(2), 169-77.
  34. Schweitzer JB, Lee DO, Hanford RB, Tagamets MA, Hoffman JM, Grafton ST, Kilts CD (2003). A positron emission tomography study of methylphenidate in adults with ADHD: alterations in resting blood flow and predicting treatment response. Neuropsychopharmacology, 28(5), 967-73.
  35. Turner RS, Grafton ST, McIntosh AR, DeLong MR, Hoffman JM (2003). The functional anatomy of parkinsonian bradykinesia. Neuroimage, 19(1), 163-79.
  36. Davis MR, Votaw JR, Bremner JD, Byas-Smith MG, Faber TL, Voll RJ, Hoffman JM, Grafton ST, Kilts CD, Goodman MM (2003). Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med, 44(6), 855-61.
  37. Howell LL, Hoffman JM, Votaw JR, Landrum AM, Wilcox KM, Lindsey KP (2002). Cocaine-induced brain activation determined by positron emission tomography neuroimaging in conscious rhesus monkeys. Psychopharmacology (Berl), 159(2), 154-60.
  38. Hamann SB, Ely TD, Hoffman JM, Kilts CD (2002). Ecstasy and agony: activation of the human amygdala in positive and negative emotion. Psychol Sci, 13(2), 135-41.
  39. Votaw JR, Howell LL, Martarello L, Hoffman JM, Kilts CD, Lindsey KP, Goodman MM (2002). Measurement of dopamine transporter occupancy for multiple injections of cocaine using a single injection of [F-18]FECNT. Synapse, 44(4), 203-10.
  40. Byas-Smith M, Frolich MA, Votaw JR, Faber TL, Hoffman JM (2002). Cerebral blood flow during propofol induced sedation. Mol Imaging Biol, 4(2), 139-46.
  41. Croft BY, Hoffman JM (2001). NCI-funded small animal imaging programs. National Cancer Institute. Acad Radiol, 8(4), 372-4.
  42. Kilts CD, Schweitzer JB, Quinn CK, Gross RE, Faber TL, Muhammad F, Ely TD, Hoffman JM, Drexler KP (2001). Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry, 58(4), 334-41.
  43. Howell LL, Hoffman JM, Votaw JR, Landrum AM, Jordan JF (2001). An apparatus and behavioral training protocol to conduct positron emission tomography (PET) neuroimaging in conscious rhesus monkeys. J Neurosci Methods, 106(2), 161-9.
  44. Hoffman JM, Croft BY (2001). Future directions in small animal imaging. Lab Anim (NY), 30(3), 32-5.
  45. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME (2001). Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA, 286(17), 2120-7.

Review

  1. Schwarz SW, Dick D, VanBrocklin HF, Hoffman JM (2014). Regulatory Requirements for PET Drug Production. [Review]. J Nucl Med, 55(7), 1132-7.
  2. Kadrmas DJ, Hoffman JM (2013). Methodology for quantitative rapid multi-tracer PET tumor characterizations. [Review]. Theranostics, 3(10), 757-73.
  3. Foster NL, Wang AY, Tasdizen T, Fletcher PT, Hoffman JM, Koeppe RA (2008). Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease. [Review]. Alzheimers Dement, 4(1 Suppl 1), S29-36.
  4. Hoffman JM, Gambhir SS (2007). Molecular imaging: the vision and opportunity for radiology in the future. [Review]. Radiology, 244(1), 39-47.
  5. Biswal S, Resnick DL, Hoffman JM, Gambhir SS (2007). Molecular imaging: integration of molecular imaging into the musculoskeletal imaging practice. [Review]. Radiology, 244(3), 651-71.
  6. Hammoud DA, Hoffman JM, Pomper MG (2007). Molecular neuroimaging: from conventional to emerging techniques. [Review]. Radiology, 245(1), 21-42.
  7. Margolis DJ, Hoffman JM, Herfkens RJ, Jeffrey RB, Quon A, Gambhir SS (2007). Molecular imaging techniques in body imaging. [Review]. Radiology, 245(2), 333-56.
  8. Hoffman JM (2001). New advances in brain tumor imaging. [Review]. Curr Opin Oncol, 13(3), 148-53.

Book Chapter

  1. Hoffman JM (2010). The Regulatory and Reimbursement Process for Imaging Agents and Devices. In Weissleder R, Gambhir S, Ross BD, Rehemtulla A, Decker BG. (Eds.), Molecular Imaging: Principles and Practice (pp. 1299-1325). Shelton CN: People's Medical Publishing.
  2. Kadrmas DJ, Rust TC, and Hoffman JM (2008). Characterization of Multiple Aspects of Tumor Physiology by Multi-Tracer Positron Emission Tomography. In M.A. Hayat (Ed.), CANCER IMAGING Volume 2: Instrumentation and Applications (Volume 2, pp. 141-53). London, UK: Elsevier Academic Press.

Conference Proceedings

  1. Zollinger LV, Morton K, Akerley WL, Kadrmas D, Christian PE, Butterfield RI, Hoffman JM (6/19/2012). 18F-FDG and FLT PET for early prediction of response to targeted chemotherapy in advanced lung cancer. Presented at Society of Nuclear Medicine 2012, Annual Meeting. SNM Program Oral Presentation #384.
  2. Duff K, Hoffman JM, Foster N, Dennett K, Thurfjell L, Wang A, Morton K, Zollinger L, Gallagher K (1/12/12). Flutemetamol is related to practice effects on cognitive testing. Human Amyloid Imaging Meeting 1/12/12-1/12/12. Miami FL. Poster #16 Page 61.
  3. Duff K, Foster N, Hoffman JM, Dennett K, Thurfjell L, Wang A, Zollinger L, Morton K, Gallagher K (01/12/12). Regional brain differences in flutemetamol uptake and practice effects. Human Amyloid Imaging Meeting 1/12/12-1/12/12. Miami FL. Poster #17 Page 62.
  4. Pack NA, DiBella EVR, Rust TC, Kadrmas DJ, McGann CJ, Butterfield R, Christian PE, Hoffman JM (2008). Estimating myocardial perfusion from dynamic contrast-enhanced MRI with a model-independent deconvolution method. Soc Card Magn Reson, , Los Angeles, #151.
  5. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D (2006). Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med, United States, 47(6), 1059-66.
  6. Doolittle ND, Abrey LE, Bleyer WA, Brem S, Davis TP, Dore-Duffy P, Drewes LR, Hall WA, Hoffman JM, Korfel A, Martuza R, Muldoon LL, Peereboom D, Peterson DR, Rabkin SD, Smith Q, Stevens GH, Neuwelt EA (2005). New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res, United States, 11(2 Pt 1), 421-8.

Abstract

  1. Mihalopoulos NL, Hoffman JM, Nanjee MN, Skidmore J, Butterfield RI, Young P (October 2011). Brown Adipose tissue does not protect obese adults from metabolic dysregulation [Abstract]. 29th Annual Scientific Meeting of the Obesity Society.
  2. Hoffman JM, Butterfield RI, Christian PE, Christensen C, Morton K (May 2011). FDG-PET/CT in the evaluation of persistent febrile neutropenia in cancer patients. Presented at Society of Nuclear Medicine 2011 Annual Meeting [Abstract]. J Nucl Med, 52(1), 1373.
  3. Hoffman JM, Butterfield RI, Christian PE, Christensen C, Morton K (July 2011). The Utility of 18F-FDG-PET/CT for the Diagnosis of Occult Malignancy in Patients with Acute, Unprovoked Venous Thromboembolism. Society for Vascular Medicine. (Poster 32). Presented at the Society of Vascular Medicine National Meeting [Abstract].
  4. Hoffman, JM, Wang LM, Wu Q, Morton K (May 1, 2011). Uptake of 2-deoxyglucose analogs by thrombotically activated cells. Presented at Society of Nuclear Medicine 2011 Annual Meeting [Abstract]. J Nucl Med, 52(1), 327.
  5. Hoffman JM, Butterfield RI, Christian PE, Heilbrun M, Morton K (May 2011). The Utility of FDG PET-CT for the diagnosis of occult malignancy in patients with acute, unprovoked venous thromboembolism [Abstract]. Society for Vascular Medicine 2011 Annual Meeting, 52(1), 1922.
  6. Marcus RL, Addison O, LaStayo PC, Hungerford R, Hoffman J, McClain DA (In Press). The Impact of Muscle Size on Whole Body and Regional Glucose Utilization [Abstract]. Diabetes,, 6.
  7. Li-Ming Wang, Qi Wu, John Hoffman, Paul Christian, Sabine Becker, and Kathryn Morton (2010). Alterations in copper uptake, content and distribution in the brains of aging mice [Abstract]. J. NUCL. Med. MEETING ABSTRACTS, 51:1759.
  8. Akerley WL, Rich NT, Egbert L, Harker WG, Van Duren T, Smit J, Hoffman JM (2010). Bevacizumab/erlotinib (BEER) as first-line treatment for untreated, advanced non-squamous non-small cell lung cancer (NSNSCLC) [Abstract]. J Clin Oncol, 28((suppl;abstr e18008)).
  9. Mihalopoulos, NL, Young, P, Holubkov, R, Hoffman, JM (2009). Brown Adipose Tissue, Body Mass Index, and Glucose in Humans. American Heart Association Council on Nutrition, Physical Activity and Metabolism [Abstract]. Tarpon Springs, FL, USA. Circulation, 119:e271-e366.
  10. Druzgal J, Anderson JS, Froelich A, Dubray M, Lainhart J, Hoffman JM (2009). Regional Homogeneity Analysis of Resting State BOLD fMRI Demonstrates between Autistics and Typically Developing Control Patients: Can we Image Cognitive Pathology? [Abstract]. Radiology Supplement 95th Scientific Meeting of the Radiologic Society of North America, SSM15-01, 597.
  11. Rodrigues RS, Bozza FA, Morton KA, Hoffman JM, Weyrich A, Zimmerman GA et al (2009). Imaging Early Events in Lung Injury [Abstract]. Radiology Supplement 95th Scientific Meeting of the Radiologic Society of North America, SSA12-07, 318.
  12. Christian PE, Smith HE, Buckway BS, Gibby J, Brooks ML, Morton KA, Hoffman JM (2008). Performance of a preloaded cassette based synthesis module for F-18 FDG production [Abstract]. 12th International Targetry Workshop, Abtract Book.
  13. Morton KA, Rodrigues RS, Bozza FA, Christian PE, Hoffman JM (2008). Comparison of standard and high resolution contrast enhanced PET/CT protocols in head and neck cancer staging [Abstract]. 2008 World Molecular Imaging Congress.
  14. Morton KA, Wang L-M, Zimmerman GA, Rodrigues RS, Bozza FA, Hoffman JM, Christian PE (2008). Characterization of uptake of D-Glucose analogs by activated thrombotic cells [Abstract]. 2008 World Molecular Imaging Congress.
  15. Schwager A, Hoffman JM (2008). Nonselective attention may decrease discrimination between experimental conditions using BOLD fMRI [Abstract]. Society for Neuroscience.
  16. Pack N, DiBella E, McGann C, Rust T, Kadrmas D, Butterfield R, Christian P, Hoffman JM (2008). Myocardial blood flow estimation using a model-independent deconvolution method at 3T MRI: comparison to 13N-ammonia PET [Abstract]. JCMR, 10(S1), 62.
  17. Levy JA, Chelune GJ, Zamrini E, Hoffman JM, Wang AY, Foster NL (2007). Pattern of impaired word generation differs in frontotemporal dementia and Alzheimer's disease [Abstract]. Journal of the International Neuropsychological Society, 13(S1), 100.
  18. Hoffman JM, Christensen CR, Morton KA (2007). Tc-99m MAA SPECT CT/MR fusion in planning for Y-90 microsphere radioembolization [Abstract]. J Nucl Med, 48(5), Supplement 2 141P.
  19. Hitchcock YJ, Morton KA, Tward JD, Hoffman JM, Sharma P, Bentz B, Shrieve DC (2006). The application of [18FDG] PET/CT in treatment planning and response evaluation for patients undergoing radiotherapy for head and neck cancer [Abstract]. Proceedings of the 48th Annual ASTRO Meeting S433.
  20. Neuwelt EA, Manninger SP, Solymosi D, Nesbit G, Jerosch-Herold M, Stevens A, Hoffman JM (2006). Initial timing of MR imaging and assessment of MR angiography using intravenous superparamagnetic dextran coted iron-oxide particles (ferumoxytol) in primary high-grade brain tumors and/or cerebral metastases [Abstract]. AJNR.
  21. Morton KA, Christensen CR, Clark PB, Hoffman JM (2006). FDG PET identifies sites of infection in cancer patients with febrile neutropenia [Abstract]. J Nucl Med, 47(5) (330P).
  22. Rust TC, DiBella EV, McGann CJ, Christian PE, J, Hoffman JM, Kadrmas DJ (2006). A rapid dual-injection method for quantification of rest and stress myocardial blood flow using 13N-ammonia PET [Abstract]. J Nucl Med, 47(5) (119P).
  23. Moeller JR, Rusinek H, Casanova MF, Hoffman JM, Votaw JR, Tune LM, Perdomoa C, Pratt RD, Ieni JR, Jewart RD (2004). Preservation of Cortical Metabolic Function by Donepezil in Patients with Mild to Moderate Alzheimer's Dementia: A 24-Week Clinical Trial With Placebo Control [Abstract]. Neuropsychopharmacology, 29(Suppli 1), S190-S191.
  24. Moeller JR, Rusinek H, Casanova MF, Hoffman JM, Votaw JR, Tune LM, Perdomoa C, Pratt RD, Ieni JR, Jewart RD (2003). Donepezil Maintains Activity in a Specific Neural Network in Patients with Alzheimer's Disease [Abstract]. Journal of Neurology, 250(suppli 2), II/71.
  25. Moeller JR, Rusinek H, Casanova MF, Hoffman JM, Votaw JR, Tune LM, Perdomoa C, Pratt RD, Ieni JR, Jewart RD (2003). Donepezil Maintains Functional Brain Activity in a Specific Neural Network in Patients with Alzheimer's Disease [Abstract]. Eur Neurol, 10(suppl 1), 2101.

Other

  1. Frank R, Badawi R, Casey M, Christian P, Clunie D, Cole P, Gagnon D, Hoffman JM, Karam L, Kinahan P, Maguire RP, Perlman E, Kohlmyer S, Nelson D, Turkington T (2008). Quantitative Imaging Biomarkers Alliance FDG–PET/CT Working Group Report. Mol Imaging Biol (10, p. 305).
  2. Rodrigues RS, Miller PR, Bozza FA, Marchiori E, Zimmerman GA, Hoffman JM, Morton KA (2008). FDG-PET in patients at risk for acute respiratory distress syndrome: a preliminary report. Intensive Care Med (34(12), pp. 2273-8). United States.
  3. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A (2007). Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark (3(1), pp. 1-33). Netherlands.

Clinical Trials

Video & News